文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

系统综述与Meta分析:胃蛋白酶原、胃泌素-17及抗幽门螺杆菌抗体血清学联合检测诊断萎缩性胃炎的诊断效能

Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-08-07

该系统综述与Meta分析检索1995年1月至2016年12月多个数据库及国际会议摘要,纳入20项以更新悉尼系统组织学为参考标准的研究、共4241名受试者,评估胃蛋白酶原、胃泌素-17和抗幽门螺杆菌抗体血清学联合检测诊断萎缩性胃炎的效能;汇总敏感度74.7%(95%CI 62.0-84.3),特异度95.6%(95%CI 92.6-97.4),在萎缩性胃炎患病率27%时阴性预测值为91%;作者认为该联合检测似乎可作为诊断萎缩性胃炎的可靠工具,或可用于胃癌高危人群的萎缩性胃炎筛查,但需进行成本效果分析。

要点

  • 血清联合检测诊断萎缩性胃炎的汇总敏感度为74.7%(95%CI 62.0-84.3)。
  • 汇总特异度为95.6%(95%CI 92.6-97.4)。
  • 萎缩性胃炎患病率27%时,阴性预测值为91%。

核心结论

  • 胃蛋白酶原、胃泌素-17和抗幽门螺杆菌抗体血清学联合检测似乎是诊断萎缩性胃炎的可靠工具。
  • 该检测或可用于胃癌高危人群的萎缩性胃炎筛查,但需进行成本效果分析。

研究设计与样本

  • 系统综述与Meta分析,检索Medline via PubMed、Embase、Scopus、Cochrane Library数据库及国际会议摘要,时间范围为1995年1月至2016年12月。
  • 纳入标准为以更新悉尼系统组织学为参考标准、评估血清联合检测诊断萎缩性胃炎准确性的研究。
  • 共纳入20项研究,合计4241名受试者。

主要发现

  • 20项研究评估了血清联合检测诊断萎缩性胃炎(不考虑胃内部位)的效能,汇总敏感度为74.7%(95%CI 62.0-84.3),汇总特异度为95.6%(95%CI 92.6-97.4)。
  • 在萎缩性胃炎患病率为27%(各研究患病率中位数)时,阴性预测值为91%。
  • 评估该检测识别萎缩性胃炎部位效能的研究较少且样本量小。

关键数值与推荐

  • 血清联合检测诊断萎缩性胃炎:汇总敏感度74.7%(95%CI 62.0-84.3),汇总特异度95.6%(95%CI 92.6-97.4)。
  • 萎缩性胃炎患病率27%时,阴性预测值为91%。

临床怎么用

  • 作者认为该血清联合检测或可用于胃癌高危人群的萎缩性胃炎筛查,但需进行成本效果分析。

局限性

  • 评估该检测识别萎缩性胃炎部位效能的研究较少且样本量小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The combination of pepsinogen, gastrin-17 and anti-H. pylori antibodies serological assays (panel test) is a non-invasive tool for the diagnosis of atrophic gastritis. However, the diagnostic reliability of this test is still uncertain. AIM: To assess the diagnostic performance of the serum panel test for the diagnosis of atrophic gastritis. METHODS: Medline via PubMed, Embase, Scopus, Cochrane Library databases and abstracts of international conferences proceedings were searched from January 1995 to December 2016 using the primary keywords "pepsinogens," "gastrin," "atrophic gastritis," "gastric precancerous lesions." Studies were included if they assessed the accuracy of the serum panel test for the diagnosis of atrophic gastritis using histology according to the updated Sydney System as reference standard. RESULTS: Twenty studies with a total of 4241 subjects assessed the performance of serum panel test for the diagnosis of atrophic gastritis regardless of the site in the stomach. The summary sensitivity was 74.7% (95% confidence interval (CI), 62.0-84.3) and the specificity was 95.6% (95%CI, 92.6-97.4). With a prevalence of atrophic gastritis of 27% (median prevalence across the studies), the negative predictive value was 91%. Few studies with small sample size assessed the performance of the test in detecting the site of atrophic gastritis. CONCLUSIONS: The combination of pepsinogen, gastrin-17 and anti-H. pylori antibodies serological assays appears to be a reliable tool for the diagnosis of atrophic gastritis. This test may be used for screening subjects or populations at high risk of gastric cancer for atrophic gastritis; however, a cost-effectiveness analysis is needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017. PMID: 28782119. doi:10.1111/apt.14248

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。